background: Although elective single embryo transfer (eSET) minimizes the multiple birth rate after in vitro fertilization (IVF)/intra cytoplasmic sperm injection (ICSI), there remain concerns in many countries that it is less effective and more expensive than conventional double embryo transfer (DET).
Introduction
There is now universal agreement that multiple pregnancies pose the biggest health risks from in vitro fertilization (IVF) and intra cytoplasmic sperm injection (ICSI); these risks arise mainly from complications related to prematurity and are commonly seen in low birthweight and intrauterine growth retardation (ESHRE, 2000) . More IVF twins than singletons are delivered by Caesarean section, and more are admitted to neonatal intensive care units . As a result, governments and professional organizations have called on those treating infertility to reduce the incidence of multiple pregnancies in IVF, with some setting limits on the number of embryos to be transferred (ESHRE, 2001 ; Practice Committees of SART and ASRM, 2006) . However, despite these moves, the worldwide total of multiple births-and especially of twin births-continues to rise (Reynolds and Schieve, 2006; Dickey, 2007) . In Europe in 1998, 7408 twin deliveries were reported following IVF/ICSI, a rate of 23.9% (Nygren and Andersen, 2001) ; by 2003 that number had increased to 10 396, a twin delivery rate of 22.0% (Nyboe Andersen et al., 2007) . In Europe in 2003, more than one embryo was transferred in 84% of cycles (Nyboe Andersen et al., 2007) ; in the USA, the proportion was even higher (99%) (Reynolds and Schieve, 2006) .
A policy of elective single embryo transfer (eSET) followed by one or several frozen-thawed embryo transfer (FET) cycles has been shown to reduce the incidence of multiple pregnancies and maintain acceptable live birth rates in both randomized controlled trials Martikainen et al., 2001; Gardner et al., 2004; Thurin et al., 2004; Lukassen et al., 2005; van Montfoort et al., 2006) and retrospective studies (Vilska et al., 1999; Tiitinen et al., 2001; Gerris et al., 2004; van Montfoort et al., 2005; Veleva et al., 2006) . Today, eSET is routinely practiced in Finland, Sweden and Belgium (Nyboe Andersen et al., 2007) , where a pronounced decrease in multiple live birth rate has already been noted (Tiitinen et al., 2004; Gordts et al., 2005; Karlströ m and Bergh, 2007) . Nevertheless, despite the evidence of this experience, a policy of eSET has not been more widely adopted because of doubts over its overall applicability (Bhattacharya and Templeton, 2004; Gleicher and Barad, 2006) . There is fear that the large-scale adoption of eSET will lower pregnancy rates per embryo transfer, increase the cost of treatment to the couple and extend the time needed to achieve pregnancy. In addition, a significant proportion of patients (20-90%) favour twins over singletons (Gleicher et al., 1995; Murray et al., 2004; Ryan et al., 2004) , partly because many cannot afford more than one treatment cycle and wish to maximize their chance of pregnancy with the transfer of more than one embryo (Ryan et al., 2004) .
IVF/ICSI treatment can be expensive, with prices differing considerably between countries. In 2002, the average price of a single treatment cycle was 2700 euros in Finland, but 10 000 euros in the USA (Collins, 2002) . Until now, the financial impact of eSET has been studied insufficiently (Scotland et al., 2007) . Several costeffectiveness analyses of relatively small groups of highly selected patients (Wølner-Hanssen and Rydhstroem, 1998; De Sutter et al., 2002; Gerris et al., 2004; Lukassen et al., 2005; Fiddelers et al., 2006; Thurin Kjellberg et al., 2006) suggest that eSET might be less expensive than double embryo transfer (DET) if IVF treatment, pregnancy and paediatric care are evaluated together, but not if the cost of the treatment alone is analysed (Fiddelers et al., 2007) . Moreover, the effect of FET cycles after eSET (De Sutter et al., 2002; Thurin Kjellberg et al., 2006) has not been fully evaluated. In the present analysis, we have assessed the applicability of eSET by studying whether its implementation is associated with changes in the cost-effectiveness of the whole IVF programme or in the cost of the treatment itself. This is the first study to evaluate the cumulative effect of a fresh IVF/ICSI cycle with subsequent FET cycles in a complete, consecutive patient population over an extended period of time. Our study, thus, reflects eSET in everyday practice, with an outcome measure consistent with what patients actually want (a healthy live birth achieved in a cost-effective way). We feel that the application of such unselected cumulative data is now the best way to describe the efficiency and outcome of any IVF programme.
Materials and Methods
Between 1995 and 2004, a total of 1510 women aged under 40 years had IVF/ICSI treatment at the Infertility Unit of the Oulu University Hospital. They had 2386 fresh cycles with ovum pickup followed by 1272 FET cycles. The analysis was performed on all consecutive fresh and FET cycles of each woman in two periods: the DET period (fresh cycles: 1995 (fresh cycles: -1999 (fresh cycles: , FET cycles: 1995 (fresh cycles: -2000 , in which eSET was used experimentally; and the eSET period (fresh cycles: 2000 (fresh cycles: -2004 (fresh cycles: , FET cycles: 2000 (fresh cycles: -2005 , in which eSET was more routinely practiced. In the DET period, 826 women had 1359 fresh and 589 FET cycles; in the eSET period, 684 women had 1027 fresh and 683 FET cycles. Baseline characteristics are shown in Table I .
Clinical procedures
Ovarian stimulation was performed with a long protocol (Veleva et al., 2008) , and embryo transfer was mostly carried out 2 days after ovum pickup. A top quality embryo was defined as having 4 -5 cells and ,20% fragmentation if cultured for 2 days, or 8 cells and ,20% fragmentation if cultured for 3 days . eSET use began in 1996. It was initially performed in the first two stimulation cycles of women who had 4 good quality embryos (Martikainen et al., 2001) . The criteria for eSET were gradually changed such that by 2004 it was performed in the first two cycles of all women with 1 top quality embryo. In all, 58.6% (602/1027) of the cycles during the eSET period had 1 top quality embryo.
Thawed embryos were transferred 3 -5 days after the luteinizing hormone (LH) surge of a natural cycle. Intravaginal progesterone (400 mg/day) was administered for 2 weeks following transfer. In cases of anovulation, hormone replacement with 4 -6 mg estradiol valerate and 600 mg/day intravaginal progesterone was given. Endometrial thickness and follicular growth (in cases of a spontaneous cycle) were assessed by ultrasound. Clinical pregnancies with cardiac activity were confirmed by transvaginal ultrasonography at gestational week 6 -7.
Statistical analysis of clinical data
Characteristics of the first treatment cycles of each woman, the FET cycles as well as cumulative data were compared by using x 2 , Mann -Whitney and t-tests, with two-tailed P , 0.05 as the limit of significance. Since the main reason for performing eSET is to lower the number of premature births, the primary clinical outcome measure chosen for this study was the proportion of women with at least one term live birth after 37 completed gestational weeks in each group (cumulative term live birth rate, cumulative tLBR). Cumulative pregnancy (cumulative PR), live birth (cumulative LBR) and multiple birth rates (cumulative MBRs) per woman and per ovum pickup were chosen as secondary outcome measures. A multiple pregnancy or birth was counted as a single event.
The independent effects of clinical and laboratory characteristics, years of follow-up and the treatment period on the cumulative pregnancy, live birth and term live birth rates were assessed by logistic regression with backward elimination after multicollinearity examination. The independent clinical effect of the change in embryo transfer policy on the cumulative term live birth rate was evaluated by using the predicted probability for term live birth for each woman in the DET period. For the same subjects, the probabilities of term live birth with the regression coefficient of the eSET period were calculated. The difference between the two probabilities showed the change in clinical outcome from DET to eSET policy.
Analysis of costs
Total treatment charges and medication costs for fresh and FET cycles until the pregnancy test were evaluated using a payer perspective that included only charges for IVF/ICSI treatment and prices of medication (Table II) . All financial calculations were performed using the pricelist of the Infertility Unit of the Oulu University Hospital for the year 2008 and a 3% discounting rate.
The hospital charge for IVF or ICSI as well as the cost of medication for ovarian stimulation with the long protocol constituted the costs of a fresh cycle. In our unit, the charge for freezing and cryostorage of supernumerary embryos is included in the fresh cycle charge. Costs resulting from complications of ovarian stimulation (ovarian hyperstimulation syndrome, bleeding and infections) were not taken into consideration.
The costs of a FET cycle included the hospital charge (including two ultrasonographic examinations, thawing and culturing of the embryo(s), and embryo transfer) and the cost of medication. The cost of the LH Cost-effectiveness of eSET test and progesterone used in a spontaneous FET cycle was roughly equal to the cost of estradiol and progesterone used in hormone replacement FET cycle; the costs of 'hormonal support' were thus analysed for every FET cycle.
The total treatment cost per woman had a multimodal distribution due to the fact that the costs of the fresh IVF or ICSI cycles were much higher than that of the FET cycles. Therefore, the treatment costs of the fresh and the FET cycles per woman were analysed separately in a multivariate general linear model after log-transformation. The independent effects of treatment period, years of follow-up and clinical and laboratory characteristics were assessed after multicollinearity examination. The following variables were included in the starting regression and general linear models: period (eSET versus DET), years of follow-up, age (,30 years, 30 -34 years and 35 years), body mass index (BMI), BMI squared (centred at 24 kg/m 2 ), diagnosis (excluding cases with multiple diagnoses in logistic regression), method of fertilization (IVF versus ICSI) and number of top quality embryos created. Variables without independent effects were removed from the model. The contrast estimate of the eSET period was used to calculate the change, in the total treatment cost of the women in the DET period, from a DET to an eSET transfer policy. 
Cost-effectiveness analysis
An incremental cost-effectiveness ratio (ICER) was defined as the ratio of D costs/D term live births. This allowed calculation of the extra cost for achieving an extra unit of effectiveness by adopting one treatment over the other (Drummond et al., 2005) . Sensitivity analysis was performed using the 95% confidence intervals (CIs) of the number of fresh and FET cycles and of the fresh and FET term live births in each period. Standard deviation (SD) of the gonadotrophin dose was used in the sensitivity analysis instead of the 95% CI given the substantial variation of gonadotrophin requirements between subjects. Finally, the range of the change in the predicted probabilities of term live birth and the range of the change in the total cost from the general linear model were used in estimating the independent effect of the change from DET to eSET policy. Best-case (most favourable to eSET) and worst-case (least favourable to eSET) scenarios were modelled to reflect joint uncertainty in all studied estimates. The relative cost of fresh and FET cycles was also evaluated. To this end, the total cost of a FET cycle was gradually increased until there was no difference in the total costs between the eSET and DET periods.
Statistical analysis was performed with SPSS 16.0 software (SPSS, Chicago, IL, USA).
Results
The outcomes of the fresh and the FET cycles are shown in Table III. In the fresh cycles, the PR and LBR per ovum pickup did not differ significantly between the two study periods. However, the cumulative PR (38.2 versus 33.1%, P ¼ 0.01), cumulative LBR (32.5 versus 27.3%, P ¼ 0.007) and cumulative tLBR per ovum pickup (28.0 versus 22.5%, P ¼ 0.001) were higher in the eSET period (Table IV) . The cumulative MBR per ovum pickup was significantly lower in the eSET period (8.7 versus 18.7%, P , 0.0001).
Taking into account all fresh and FET treatments of each patient, the cumulative PR and cumulative LBR per woman were similar in the two periods. The cumulative tLBR per woman was higher (41.7 versus 36.6%, P ¼ 0.04) and the cumulative MBR per woman more than two times lower in the eSET than in the DET period (8.9 versus 19.6%, P , 0.0001).
Women in the eSET period had fewer fresh and more FET cycles than those in the DET period. The total number of cycles per woman (2.5 + 1.7 versus 2.4 + 1.6, P ¼ 0.06) was similar in both periods. The mean times of treatment were 8.8 + 10.1 months in the eSET period and 9.5 + 11.8 months in the DET period (P ¼ 0.8). The majority of live births occurred within four consecutive cycles (fresh plus FET): 90.7% (302/333) of the live births in the eSET period and 93.3% (348/373) of the live births in the DET period (P ¼ 0.2). The proportion of women who experienced ovarian hyperstimulation syndrome after ovarian stimulation tended to be lower in the eSET period than in the DET period (65/684, 9.5% versus 105/826, 12.7%, P ¼ 0.05).
Regression analyses
Logistic regression revealed that the eSET period increased independently the odds of pregnancy (odds ratio (OR): 1.39 and 1.23 per ovum pickup and per woman, respectively) and the odds of term live birth (OR: 1.43 and 1.37 per ovum pickup and per woman, respectively) ( Table V) . The probabilities of term live birth of subjects were higher in the eSET period than in the DET period (mean + SD of the difference: 0.060 + 0.007; 95% CI: 0.059-0.060; range: 0.011-0.070). The multivariate general linear model showed that the eSET period diminished the cost of the fresh cycles (OR: 0.95, P , 0.0001) but not the cost of the FET cycles (P ¼ 0.07). The total treatment costs per woman decreased by 275 euros (range 21184 to -164 euros). This was 4.7% (275/5890) of the total treatment price per woman in the DET period (Table VI) .
Cost-effectiveness
Total undiscounted costs were 3 837 964 euros during the eSET period and 4 865 304 euros during the DET period (Table VI) . After discounting, costs per woman were lower and the number of term live births was higher in the eSET, compared with the DET period. The ICER was equal to 219 889 euros, meaning that 19 889 euros were saved per term live birth in the eSET period, compared with the DET period. In all steps of the sensitivity analysis (Table VII) , the eSET period was associated with more term live births and with lower total costs than was the DET period. The ICER was always negative, indicating that eSET was the less costly treatment.
Sensitivity analysis showed that an eSET programme would provide savings and would improve live birth rate under any scenario. The Cost-effectiveness of eSET worst-case scenario was found when the lower 95% CI of the number of cycles and that of the tLBR associated with both the fresh and the FET cycles were used together with the lower SD of the FSH cost (cost difference 2191.11 euros, term live birth difference 0.0163 and ICER 211 725). The best-case scenario was found under the opposite conditions, when the upper 95% CI of the number of cycles and that of the tLBR associated with both the fresh and the FET cycles were used together with the upper SD of the FSH cost (cost difference 2400.86 euros, difference in term live births 0.0288 and ICER 213 919).
The total cost of a FET cycle (including the hospital charge and medication cost) was 666 euros, 22% of the total cost of an IVF cycle (3070 euros) and 18% of the total cost of an ICSI cycle (3887 euros). We gradually increased the total cost of a FET cycle until there was no difference in total cost between the eSET and DET periods. This was only reached when the total cost of a FET cycle was 3833.50 euros, 125% of the total cost of an IVF cycle and 98.6% of the total cost of an ICSI cycle.
Discussion
The present study shows that the implementation of an eSET policy together with an effective cryopreservation programme results in a better outcome and lower treatment costs for women under the age of 40 having IVF/ICSI.
In our unit, eSET was started in 1996 and throughout the study period until 2004, the proportion of eSET cycles increased to 46.2%. Despite this remarkable decrease in the number of fresh embryos transferred, the cumulative LBR per woman in our overall patient population remained unchanged, whereas the cumulative MBR per woman decreased substantially. This finding is consistent with the Finnish national registry data, which also show a steady decrease in the proportion of multiple births after IVF/ICSI-from 24% in 1996 to 14% in 2002-with an unchanged LBR (Tiitinen et al., 2004) . Similar results have since been reported from other countries adopting an eSET policy (Gordts et al., 2005; Karlströ m and Bergh, 2007) .
There is no present agreement on the most appropriate outcome measure of an IVF/ICSI programme. Previous eSET studies, which defined the outcome in terms of pregnancy per single cycle, did confirm low multiple pregnancy rates, but at the cost of a lower pregnancy rate per transfer Martikainen et al., 2001; Bhattacharya and Templeton, 2004; Thurin et al., 2004; Lukassen et al., 2005; van Montfoort et al., 2006) . In contrast, by adopting cumulative outcome measures, which take into account both fresh and FET transfers (Tiitinen et al., 2004) , we could demonstrate a higher chance of pregnancy per ovum pickup and per woman (ORs: 1.39 and 1.23, respectively) in the eSET period than in the DET period in our patient population. Moreover, in order to incorporate the safety aspects of treatment (ESHRE, 2000) , our main clinical outcome measure was based on the term live birth after 37 full gestational weeks which, in our opinion, is the measure most closely related to the eSET concept. In the eSET period, the tLBR per woman was higher than in the DET period because of the reduced number of multiple births, even after analysis of confounding factors Veleva et al., 2008) .
The higher cumulative pregnancy rate during the eSET period can be explained by more effective use of cryopreserved embryos. During the DET years, embryos were frozen in groups of at least three whenever possible (mean number of embryos in the vial 3.8 + 1.6). By contrast, during the eSET period, top quality embryos have been mostly frozen in individual vials, resulting in a lower mean number of embryos (top and non-top quality) in the same vial (2.9 + 1.2, P , 0.0001) and a higher number of single embryo transfers in FET (DET: 94/589 (16.0%) versus eSET: 170/683 (24.9%), P , 0.0001), allowing more FET treatments. We believe that this is the reason for the higher pregnancy rate per transfer in FET during the eSET period, and this helps to increase the cumulative pregnancy rate per woman in the whole of the eSET period.
About 90% of the deliveries in both study periods occurred within the first four treatment cycles, which suggests that the time to delivery with eSET is no longer than that found with DET-contrary to what has been proposed (Gleicher and Barad, 2006) . This is explained by the fact that several FET cycles can be performed in a short period of time. 
Cost-effectiveness of eSET
This study is the first one to evaluate the overall cost-effectiveness of an eSET policy in everyday clinical practice. Previous costeffectiveness analyses have used highly selected patients and predetermined treatment protocols, which have limited the validity of their results (Drummond et al., 2005) . When evaluating just the costeffectiveness of fresh cycles, these studies have found that eSET is inferior to DET transfer, either because of lower live birth rate (Wølner-Hanssen and Rydhstroem, 1998; De Sutter et al., 2002; Gerris et al., 2004; Lukassen et al., 2005; Fiddelers et al., 2006) or higher costs (Thurin Kjellberg et al., 2006; Bhatt and Baibergenova, 2008) . The discrepancy between these and the present analysis can be explained by the high number of FET cycles in the eSET period, which are much cheaper than fresh cycles. A higher proportion of all deliveries resulted from FET cycles in the eSET period than in the DET period (49 versus 35%). This underlines the value of cryopreservation (Martikainen et al., 2001; Tiitinen et al., 2001) , which until now has been underestimated in most countries. This is partly explained by the fact that, if two or more embryos are routinely transferred, few patients will have any good quality embryo(s) left to be frozen, and the chance of pregnancy in any subsequent FET cycles would consequently remain low. Accordingly, in our study, the pregnancy rate in FET cycles increased from 17% in the DET period to 24% in the eSET period, reflecting better embryo implantation potential.
Any concerns about the cost implications of an eSET policy (Bhattacharya and Templeton, 2004; Gleicher and Barad, 2006) are refuted by the present results. A previous study from our unit has shown that costs of maternal and paediatric care up to the end of the neonatal period were 5780 euros for a singleton and 15 582 euros for an IVF twin pair (Koivurova et al., 2004) . If these data were included in the present analysis, the ICER would have increased 1.9-fold to 36 889 euros per term live birth in favour of eSET. Accordingly, several earlier cost-effectiveness analyses have found lower overall costs with eSET if expenses for pregnancy, neonatal and paediatric care are also taken into account (Gerris et al., 2004; Fiddelers et al., 2006; Thurin Kjellberg et al., 2006) .
Because term live birth is more likely and less expensive with eSET and cryopreservation, IVF/ICSI treatment is affordable for more patients. A recent analysis indicated that, even in developed countries, only 22% of infertile patients receive IVF/ICSI treatment (Boivin et al., 2007) , mainly because of treatment costs, which can be as much as 25% of annual household expenditures (Collins, 2002) . If the adoption of eSET allows a treatment cost reduction of 4.7% (as shown in the present study), a 14.1% rise in uptake might be expected as a result of the high price elasticity of the method (3.0) (Collins, 2002) .
In order to promote the adoption of an eSET policy in countries where IVF/ICSI treatment is supported by the health insurance policies, it is essential to consider not just the direct costs of treatment but also the costs associated with multiple births. Limiting the number of reimbursed cycles may lead to increased number of multiples, and thereby a higher total social cost. In all countries where eSET is routinely practiced, a decreased number of multiple births has been reported alongside an unchanged pregnancy rate (Tiitinen et al., 2004; Gordts et al., 2005; Karlströ m and Bergh, 2007; Nyboe Andersen et al., 2007) ; this suggests that the analysis made in Finland would be valid also in other countries. Our data support the proposals of Ledger et al. (2006) that many more treatment cycles could be funded from the savings made by adopting a policy of eSET.
In this study, fresh embryos were transferred 2 -3 days after oocyte collection. Day 5 eSET has also been shown to reduce multiple birth rate without compromising the overall outcome after a 2-year observation period (Khalaf et al., 2008) . Based on this study, one could expect similar beneficial changes in cumulative term live births and overall costs with Day 5 eSET as observed in the present study.
In conclusion, the present study provides evidence for the superiority of eSET over the traditional transfer of two embryos. Outcome is improved, overall costs are decreased because of the incorporation of FET cycles and the incidence of multiple births is reduced more than 2-fold. These data should encourage clinics to evaluate their embryo transfer policy and adopt eSET as their everyday practice.
